Select a Category
Radiopharmaceutical Therapy
Click on a publication's title to access a PDF or read an abstract.
MRT Literature Syllabus
Personalized Dosimetry for MRT: Why does it Matter?
Eberlein U, Cremonesi M, and Lassmann M. Individualized dosimetry for theranostics: Necessary, nice to have, or counterproductive? J Nucl Med2017; 58(Suppl 2): 97S-103S.
Stabin MG, Madsen MT, and Zaidi H. Personalized dosimetry is a must for appropriate molecular radiotherapy. Med Phys 2019; 46(11): 4713–4716.
Strigari L, Konijnenberg M, Chiesa C, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014; 41(10):1976-1988.
Personalized Dosimetry for MRT: How to Achieve it?
Nelson AS, Mirando D, Kruzer A, and Niman R. Dosimetry for Targeted Molecular Radiotherapy (White Paper).
Dewaraja YK, Ljungberg M, Green AJ, et al. MIRD pamphlet No. 24:Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med2013; 54(12): 2182-2188.
Sarrut D, Halty A, Badel J, et al. Voxel-based multimodal fitting method for modeling time activity curves in SPECT images. Med Phys 2017; 44(12):6280-6288.
Lamba N, Wan H, Kruzer A, et al. Clinical utility of a 3D convolutional neural network kidney segmentation method for radionuclide dosimetry. J NuclMed 2019; 60(Suppl 1): 267.
Quantitative SPECT Reconstruction
Nelson AS and Horstman BP. Quantitative SPECT / CT Reconstruction with SPECTRA TM Quant (White Paper).
Ritt P, Vija H, Hornegger J, et al. Absolute quantification in SPECT. Eur J NuclMed Mol Imaging 2011; 38(Suppl 1): 69–77.
Dewaraja YK, Frey EC, Sgouros G, et al. MIRD Pamphlet No. 23: QuantitativeSPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy. J Nucl Med 2012; 53:1310-1325.
Peters SMB., Meyer Viol SL, van der Werf NR, et al. Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems. EJNMMI Phys 2020; 7(1): 9 (2020).
Dosimetry for Patient Outcome Prediction and Treatment Planning: Lu-177
Ilan E, Sandström M, Wassberg C, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015; 56(2):177-182.
Del Prete M, Buteau F, Arsenault F, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging 2019; 46: 728‑742.
Mirando D, Dewajara YK, Kruzer A, and Nelson A. Personalized therapy planning for 177Lu-DOTATATE using a kidney-driven dose optimization method. J Nucl Med 2019; 60(Suppl 1): 270.
Mora-Ramirez E, Santoro L, Cassol E, et al. Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy. Med Phys. 2020; 47(9): 4602-4614.
Sundlöv A, Sjögreen-Gleisner K, Svensson J, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging 2017; 44(9): 1480–1489.
Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005; 46(Suppl 1):99S-106S.
Cremonesi M, Ferrari ME, Bodei L, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 2018; 45(13): 2426–2441.
Dosimetry for Patient Outcome Prediction and Treatment Planning: I-131
Flux GD, Haq M, Chittenden SJ, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 270–275.
Gregory RA, Murray I, Gear J, et al. Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy. Phys Med Biol. 2019; 64(24):245013.
Hybrid SPECT/Planar Dosimetry
Cole NM, Mirando D, Nelson AS, et al. Hybrid SPECT/Planar Dosimetry for Targeted Molecular Radiotherapy (White Paper).
Sjogreen K, Ljunberg M, Strand S. An Activity Quantification Method Based on Registration of CT and Whole-Body Scintillation Camera Images, with Application to 131I. J Nucl Med 2002; 43:972-982.
Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR, Weber DA, Brill AB. MIRD Pamphlet 16: Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates. J Nucl Med 1999; 40:37S-61S.
Single Timepoint Dosimetry
Cole NM, Mirando D, Nelson AS. Dosimetry for Targeted Molecular Radiotherapy Using a Single Measurement Timepoint (White Paper).
Hänscheid H, Lapa C, Buck AK, et al. Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days. Nucl Med. 2018; 59(1):75-81.
Garske U, Sandström M, Johansson S, et al. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol. 2012; 51(1):86-96.
Willowson KP, Eslick E, Ryu H, et al. Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (‘Lutate’) therapy. EJNMMI Phys. 2018; 5(1):33.
Del Prete M, Arsenault F, Saighi N, et al. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI Phys. 2018; 5(1):25.
Jackson PA, Hofman MS, Hicks RJ, et al. Radiation dosimetry in 177Lu-PSMA-617 therapy using a single post-treatment SPECT/CT: A novel methodology to generate tissue-specific dose factors. J Nucl Med. 2019; 61(6).